Full results & analysis
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Topical Minocycline for Symptomatic Oral Lichen Planus
NCT01083420Phase 3
Key facts
- Status
- Unknown
- Start
- Mar 2010
- Primary completion
- Mar 2011
- Sponsor
- Sheba Medical Center
- Modality
- Small Molecules
- Drugs
- minocycline
- Conditions
- oral lichen planus (OLP)
01
Overview
Phase 3, randomised trial of minocycline in oral lichen planus (OLP) (2 arms), sponsored by Sheba Medical Center. Primary endpoint: Symptoms relief at 14 days. Status: unknown.
02
Design
2 arms- Study design
- Randomized
Minocycline
Minocycline 0.2% mouthwash
Dexamethasone
Dexamethasone 0.01% mouthwash
03
Who it enrols
Patients with biopsy-proven symptomatic Oral Lichen Planus. Excludes patients with known allergy to Dexamethasone or Minocycline and pregnant women.
04
Endpoints
Primary
Symptoms relief
Beyond the preview
Go deeper on NCT01083420.
Full results, competitive context and analysis are in the Gosset platform.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01083420.